EUCTR2004-003055-40-ES进行中（未招募）不适用
A PHASE 2 MULTICENTER EVALUATION OF THESAFETY AND EFFICACY OF TOCOSOL™ PACLITAXEL(S-8184 PACLITAXEL INJECTABLE EMULSION) INPATIENTS WITH METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a)Histologic diagnosis of TCC of the urothelium including bladder, renal pelvis, ureter, or urethra. Patients with mixed tumors (i.e. tumors containing elements of squamous cell or adenocarcinoma in addition to transitional cell carcinoma) are eligible, but patients with pure non-transitional cell carcinoma are not.
- •b)Stage IV disease, i.e., metastatic (any T any N M1) or locally advanced (T4b N0 M0 or any T N1-3 M0) disease deemed incurable by surgical resection
- •c)One and only one prior systemic cytotoxic chemotherapy regimen administered as adjuvant or neoadjuvant chemotherapy or to treat locally advanced or metastatic disease. (Intravesical treatments are not included in the definition of systemic cytotoxic chemotherapy.) Prior chemotherapy should have included a minimum of two cycles of standard dose MVAC (methotrexate, vinblastine, Adriamycin and cisplatin) or cis/carboplatin and gemcitabine. Other prior chemotherapy regimens of presumed comparable efficacy and dose intensity may be acceptable if approved by the Sonus Medical Director or his designee.
- •d)Adequate hematologic function (ANC > 1500 cells/mm3 and platelet count >100,000/mm3)
- •e)Serum creatinine < 2.0 mg/dL
- •f)Total bilirubin < 1.5 mg/dL
- •g)SGOT and SGPT < 3 times the upper limit of institutional normal values
- •h)PT (INR) and PTT within institutional laboratory normal range
- •i)Karnofsky performance status of 60-100% (see Appendix 2)
- •j)At lease one unidimensionally measurable lesion, suitable for radiographic evaluation of disease response, consistent with RECIST criteria (see Section 9.2, Appendix 4 and Reference 14)
- •k)A signed IRB / Ethics Committee-approved Informed Consent
- •l)Life expectancy of at least 12 weeks
- •m)18 years of age or older
- •n)Fully recovered from any previous surgery (at least 4 weeks since major surgery)
- •o)Not pregnant and willing to use a medically effective form of contraception during periods of chemotherapy treatment (both males and females, unless surgically sterilized or post-menopausal females).
- •p)Agree not to take vitamin E supplementation while receiving study medication.
- •q)Willing to participate in requested follow-up evaluations for 1 month after completion of treatment, or until treatment-related toxicities have resolved or clinically stabilized.
- •r)Willing to permit treating physicians to provide information to the Sponsor regarding disease status and survival for 2 years after the first dose of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a)Prior taxane-containing chemotherapy including Taxol (paclitaxel) or generic equivalent, or Taxotere (docetaxel)
- •b)Peripheral neuropathy NCI-CTC grade 2 or greater
- •c)Wide-field radiation (radiation to more than 20% of the marrow bearing skeleton), cytotoxic chemotherapy or hormonal therapy within 4 weeks of first dose, or mitomycin or nitrosoureas within 6 weeks of first dose, of study drug
- •d)An investigational agent within 4 weeks of first dose of study drug
- •e)Concurrent anticonvulsants known to induce P450 isoenzymes
- •f)Patients who are pregnant or lactating
- •g)A history of carcinoma of another primary site (other than non-melanoma skin cancers or carcinoma-in-situ of the cervix) within the previous 5 years, unless metastatic disease has been biopsied and documented to be TCC
- •h)Bone metastasis, effusions, ascites or elevated tumor markers as the only evidence of metastatic TCC. (Patients with these findings in addition to a measurable target lesion are eligible.)
- •i)Brain metastasis
- •j)Active bowel obstruction
- •k)Active, serious infection or other serious medical problems (other than TCC) likely to impair completion of the study protocol. (Any ambiguous clinical circumstances must be reviewed and approved by a Sonus Medical Director).
研究者
相似试验
进行中（未招募）
1 期
A PHASE 2 MULTICENTER EVALUATION OF THE SAFETY AND EFFICACY OF TOCOSOL ® PACLITAXEL (S-8184 PACLITAXEL INJECTABLE EMULSION) IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED, UNRESECTABLE TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUMEUCTR2004-003055-40-GBSONUS Pharmaceuticals Inc.44
进行中（未招募）
2 期
A multi center, phase 2 study to Evaluate safety and efficacy of total Neoadjuvant treatment of long courSE radiotherapy followed by cheMotherapy, capecitaBine combined with oxaliplatin (CAPOX) for Locally advanced rEctal cancer(ENSEMBLE-2)JPRN-jRCTs071210143KAGAWA Yoshinori27
进行中（未招募）
1 期
Study designed to assess the safety and efficacy of the use of a reduced-intensity conditioning regimen before transplantation and of cyclophosphamide after transplantation, in patients with poor prognosis lymphoma undergoing bone marrow transplant from a partially identical donor without elimination of lymphocytes T.EUCTR2012-005580-27-ITISTITUTO CLINICO HUMANITAS47
进行中（未招募）
不适用
A multicenter phase II study to evaluate the safety, tolerability and efficacy of caspofungin as prophylactic treatment of invasive fungal infections in patients with acute leukemia undergoing induction chemotherapy - ProFIL-CneutropeniaMedDRA version: 6.1Level: PTClassification code 10049085EUCTR2006-004432-70-ITAZIENDA OSPEDALIERA SPEDALI CIVILI DI BRESCIA
进行中（未招募）
不适用
A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-targeted therapiesEUCTR2009-017871-13-PLew Medical Enzymes AG